Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Karim Fizazi; Neal Shore; Teuvo Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Iris Kuss; Marie-Aude Le Berre; Oana Petrenciuc; Amir Snapir; Toni Sarapohja; Matthew Smith

doi:10.1016/j.annonc.2020.10.443

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Karim Fizazi, Neal Shore, Teuvo Tammela, Albertas Ulys, Egils Vjaters, Sergey Polyakov, Mindaugas Jievaltas, Murilo Luz, Boris Alekseev, Iris Kuss, Marie-Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith

Research output: Other conference contribution › Abstract › Scientific

Original language	English
DOIs	https://doi.org/10.1016/j.annonc.2020.10.443
Publication status	Published - 22 Nov 2020
Publication type	Not Eligible
Event	ESMO Asia 2020 - Duration: 20 Nov 2020 → 22 Nov 2020 https://www.esmo.org/meetings/past-meetings/esmo-asia-2020-virtual

Conference

Conference	ESMO Asia 2020
Period	20/11/20 → 22/11/20
Internet address	https://www.esmo.org/meetings/past-meetings/esmo-asia-2020-virtual

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2020.10.443

Cite this

Fizazi, K., Shore, N., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M.-A., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Abstract from ESMO Asia 2020. https://doi.org/10.1016/j.annonc.2020.10.443

@conference{160c35cd36e241c98e18d5456d1c5a95,

title = "Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)",

author = "Karim Fizazi and Neal Shore and Teuvo Tammela and Albertas Ulys and Egils Vjaters and Sergey Polyakov and Mindaugas Jievaltas and Murilo Luz and Boris Alekseev and Iris Kuss and {Le Berre}, Marie-Aude and Oana Petrenciuc and Amir Snapir and Toni Sarapohja and Matthew Smith",

year = "2020",

month = nov,

day = "22",

doi = "10.1016/j.annonc.2020.10.443",

language = "English",

note = "ESMO Asia 2020 ; Conference date: 20-11-2020 Through 22-11-2020",

url = "https://www.esmo.org/meetings/past-meetings/esmo-asia-2020-virtual",

}

Fizazi, K, Shore, N, Tammela, T, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Kuss, I, Le Berre, M-A, Petrenciuc, O, Snapir, A, Sarapohja, T & Smith, M 2020, 'Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)', ESMO Asia 2020, 20/11/20 - 22/11/20. https://doi.org/10.1016/j.annonc.2020.10.443

TY - CONF

T1 - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

AU - Fizazi, Karim

AU - Shore, Neal

AU - Tammela, Teuvo

AU - Ulys, Albertas

AU - Vjaters, Egils

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Luz, Murilo

AU - Alekseev, Boris

AU - Kuss, Iris

AU - Le Berre, Marie-Aude

AU - Petrenciuc, Oana

AU - Snapir, Amir

AU - Sarapohja, Toni

AU - Smith, Matthew

PY - 2020/11/22

Y1 - 2020/11/22

UR - https://www.esmo.org/meetings/past-meetings/esmo-asia-2020-virtual

U2 - 10.1016/j.annonc.2020.10.443

DO - 10.1016/j.annonc.2020.10.443

M3 - Abstract

T2 - ESMO Asia 2020

Y2 - 20 November 2020 through 22 November 2020

ER -

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Conference

UN SDGs

Access to Document

Other files and links

Cite this